published meta-analysis   sensitivity analysis   studies

interferon in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias Emergency room visit or hospitalizationdetailed resultsTOGETHER interferon lambda, 2022 0.47 [0.29; 0.77] 0.47[0.29; 0.77]TOGETHER interferon lambda, 202210%1,936NAnot evaluable death D28detailed resultsTOGETHER interferon lambda, 2022 0.28 [0.03; 2.49] 0.28[0.03; 2.49]TOGETHER interferon lambda, 202210%1,936NAnot evaluable deathsdetailed resultsTOGETHER interferon lambda, 2022 0.28 [0.03; 2.49] 0.28[0.03; 2.49]TOGETHER interferon lambda, 202210%1,936NAnot evaluable hospitalizationdetailed resultsTOGETHER interferon lambda, 2022 0.56 [0.33; 0.96] 0.56[0.33; 0.96]TOGETHER interferon lambda, 202210%1,936NAnot evaluable viral clearance by day 7detailed resultsFeld, 2021 4.12 [1.08; 15.71] 4.12[1.08; 15.71]Feld, 202110%60NAnot evaluable0.210.01.0relative treatment effectwww.metaEvidence.org2024-04-27 09:40 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 517,881,904,882,897,896,899,1235,898,687,740,883,947 - roots T: 290